||F-15599 is a highly selective G-protein biased 5-HT1A receptor agonist with Ki value of 3.4nM.
||CA-5f is identified as a potent late-stage macroautophagy/autophagy inhibitor via inhibiting autophagosome-lysosome fusion. It exhibted potential clin
||ADH-503 is a potent agonist of the integrin CD11b to mitigate myeloid cell immunosuppression.
||PH-002 is an inhibitor of apolipoprotein (apo) E4 intramolecular domain interaction in neuronal cells that could rescue impairments of mitochondrial m
||Mc-Val-Ala-PAB is a useful ADC linker conjugating for targeting drug delivery.
||Fmoc-Val-Ala-PAB is a useful ADC linker conjugating for targeting drug delivery.
||GNF4877 is a potent DYRK1A and GSK3β inhibitor with IC50s of 6 nM and 16 nM, respectively
||Grp94 Inhibitor-1 is a potent, selective Grp94 inhibitor with an IC50 value of 2 nM, and over 1000-fold selectivity to Grp94 against Hsp90α.
||Lotamilast (RVT-501; E6005) is a selective phosphodiesterase 4 (PDE4) inhibitor with an IC50 of 2.8 nM.
||BCI-215 is a hyperactivator of fibroblast growth factor signaling that is devoid of developmental toxicity and restores defective MAPK activity caused
||O-304 is a first-in-class, orally available pan-AMPK activator, which increases AMPK activity by suppressing the dephosphorylation of pAMPK. O-304 exh
||AST2818 mesylate is an EGFR inhibitor.
||JNJ-632 is a hepatitis B virus (HBV) capsid assembly modulator (CAM).
||TP353 is a CDK7 inhibitor.
||MRTX1257 is a selective, covalent K-Ras G12C inhibitor with oral activity in animal models of cancer.
||CC-90011 is a potent and orally active LSD1 inhibitor. It is in phase I clinical study of CC-90011 in patients (pts) with advanced unresectable solid
||Fluorofenidone attenuates the progression of renal interstitial fibrosis partly by suppressing NADPH oxidase and ECM deposition via the PI3K/Akt signa
||PF-06882961 is a potent and orally bioavailable GLP-1R agonist.
||AT-007 is a central nervous system (CNS) penetrant Aldose Reductase inhibitor (ARI) in Phase 1/2 development for treatment of Galactosemia.
||GSK-25 is a ROCK1 inhibitor with IC50 value of 6nM. It showed oral bioavailability (49% in rat and 19% in monkey), good half-life (1.8 h in rat and 2.
||SBI-115 is a GPBAR1 (TGR5) antagonist.
||UBCS039 is a specific Sirtuin 6 activator which showed robust activating effects on Sirt6-dependent H3K18ac deacetylation of both full-length histone
||YAP-TEAD Inhibitor 1 TFA
||YAP-TEAD Inhibitor 1 is an inhibitor of this YAP-TEAD protein-protein interaction which has potential usage in treatment of YAP-involved cancers with
||Cl-amidine is a peptidylarginine deminase (PAD) inhibitor, with an IC50 5.9±0.3 μM for PAD4.
||Adenosine amine congener
||Adenosine amine congener hydrate is a potent aqueous-soluble A1 adenosine receptor agonist with Ki value of 0.85nM for binding against [3H]N6-cyclohex
||PK11007 is mild thiol alkylator with anticancer activity in several cell lines, especially those with mutationally compromised p53.
||CCG-222740 is a Rho/MRTF pathway inhibitor. It decreases the activation of stellate cells in vitro and in vivo, by reducing the levels o
||Emodepside is an antiparasitic that is effective against a number of gastrointestinal nematodes, used in cat.
||EC5026 is a first-in-class, small molecule that potently inhibits soluble Epoxide Hydrolase (sEH), a key regulatory enzyme involved in the metabolism
||sb4 is a potent BMP4 agonist.
||Raphin1 was orally bioavailable, crossed the blood-brain barrier, and demonstrated efficacy in a mouse model of Huntington's disease. In cells, Raphi
||Ibrolipim is a Lipoprotein lipase activator.
||PK150 is an analogue of Sorafenib, with oral bioavailability and antibacterial activity against several pathogenic strains at submicromolar concentrat
||PBD-150 is a potent glutaminyl cyclase (QC) inhibitor with Ki of 60 nM.
||TLX agonist 1
||TLX agonist 1 (ccrp2) is an orphan nuclear receptor tailless (TLX, NR2E1) modulator with EC50 of 1μM and Kd of 650 nM.
||ABT-724 3HCl is a potent and highly selective dopamine D4 receptor agonist with EC50s of 12.4 nM, 14.3 nM and 23.2 nM for human dopamine D4 receptor,
||CID-1067700 is a potent and competitive inhibitor of Ras-related GTPases inhibitor, and competitively inhibits Ras-related in brain 7 (Rab7) with a Ki
||CCT128930 is a potent ATP-competitive, selective Akt2 inhibitor with an IC50 of 6 nM and > 28-fold selectivity for Akt2 than the closely related PKA k
||Neurotensin Fragment 8-13 is the smallest active fragment of neurotensin which is a potent cellular mitogen for various colorectal and pancreatic canc
||EIDD-2801 is an orally bioavailable prodrug of EIDD-1931, which has a broad-spectrum antiviral activity against 39 multiple coronaviruses, including S
||Danicopan is selective and orally active small-molecule factor D inhibitor, shows high binding affinity to human Factor D with Kd value of 0.54 nM. It
||CADD522 is a small molecule that inhibits the DNA binding of RUNX2. It negatively regulated transcription of RUNX2 target genes such as matrix metallo
||OGG1 Inhibitor O8
||O8 OGG1 Inhibitor is an inhibitor of OGG1 with IC50 value of 0.35μM in fluorescence-based OGG1 assays. It can inhibit Schiff base formation during OGG
||Mycro3 is a small-molecule inhibitor of Myc-Max dimerization. The average residual tumor of Pdx1-cre/KRAS* mice after Mycro3 treatment (100mg/kg, oral
||MAC-545496 is a nanomolar inhibitor of GraR. It reverses β-lactam resistance in the community-acquired MRSA USA300 strain.
||VLX600 is preferentially active against quiescent cells in colon cancer 3-D microtissues. VLX600 shows enhanced cytotoxic activity under conditions of
||JCN037 is a potent EGFR inhibitor with IC50 values of 2.49 nM, 3.95 nM and 4.48 nM for EGFR, p-wtEGFR and pEGFRvⅢ, respectively. It displayed potent a